Allergy Therapeutics Plc (AGY) Ord GBP0.01
- Add to watchlist
- Create an alert
- This stock can be held in a
5.25p
5.50p
6.05p
£243.09 million
5.20p
5.00p
1.75p
n/a
0.30p (5.45%) Previous:
0.30p
620,227
n/a
150,000
Performance
Not available for this stock.
Fundamental data
Year ending: | 30/06/2024 | 30/06/2023 |
---|---|---|
Revenue (£m) | 55.20 | 59.59 |
Profit before tax (£m) | (39.17) | (41.77) |
Adjusted EPS (p): | (1.07) | (6.43) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Allergy Therapeutics starts dosing peanut allergy vaccine candidate
27 March 2023 15:16
-
Allergy Therapeutics confident in funding as results remain late
20 January 2023 12:33
-
Allergy Therapeutics pauses production at Freeman facility
4 October 2022 14:10
-
Notice of 2024 Annual General Meeting
21 November 2024 07:00
-
Audited Preliminary Results 2024
6 November 2024 07:00
-
Commencement of Phase III Paediatric Trial
21 October 2024 07:00
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.